Overview

Teneligliptin-Glimepiride DDI Study

Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
0
Participant gender:
Male
Summary
An open label, one sequence study to investigate the pharmacokinetic drug interaction between Teneligliptin and Glimepiride in healthy male subjects
Phase:
Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Handok Inc.
Handok Pharmaceuticals Co., Ltd.
Treatments:
Glimepiride
Criteria
Inclusion Criteria:

1. Healthy male adult aged 20 to 45 years

2. Body weight ≥ 50kg, and BMI between 18 and 29 kg/m2 at screening

3. Subject who agrees to use a medically acceptable double-barrier method of
contraception and not to donate sperms from the first dose until 2 months after the
last dose.

4. Subject who was given, and fully understood, the information about the study, and has
provided voluntary written informed consent to participate in the study and agreed to
comply with the study requirements.

Exclusion Criteria: